-Saccharomyces cerevisiae strains used in this study.
In yeast, eRF1 and eRF3 are encoded by SUP45 and SUP35 genes, respectively. For clarity, in this manuscript we refer to SUP45 and SUP35 as eRF1 and eRF3.
Yeast strains
Strain Genotype Source SKY1001 L40 after GuHCl treatment This study, (Van Criekinge and Beyaert 1999) MATa, ade2-1; his3-11,15; leu2-3,112; ura3-1; trp1-1; can1-100 SKY1081 MAT a, ade2-1; his3-11,15; leu2-3,112; ura3-1; trp1-1; can1-100; eRF3::eRF3AAA-HIS3MX This study SKY1085 MAT a, ade2-1; his3-11,15; leu2-3,112; ura3-1; trp1-1; can1-100; eRF3::eRF3-HIS3MX This study SKY1182 MAT a, ade2-1; his3-11,15; leu2-3,112; ura3-1; trp1-1; can1-100; eRF3::eRF3NM(253-685) 
W303-1B

-HIS3MX
This study MAT a, 15; 112; ura3; trp1; ::TRP1Kl
SKY1247
SKY1248
SKY1259
SKY1263
This study SKY1264 MAT a, ade2-1; his3-11,15; leu2-3,112; ura3; trp1; can1-100; eRF3PAB1 This study SKY1265 MAT a, ade2-1; his3-11,15; leu2-3,112; ura3; trp1; can1-100; eRF3; pab1(1-405) ::TRP1Kl This study MAT a, 15; 112; ura3; trp1; 
SKY1266
-HIS3MX;PAB1
This study SKY1289 MAT a, ade2-1; his3-11,15; leu2-3,112; ura3; trp1; can1-100; eRF3 ; PAB1 This study SKY1291 MAT a, ade2-1; his3-11,15; leu2-3,112; ura3; trp1; can1-100; eRF3::eRF3AAA-HISMX6 ; PAB1 This study SKY1317 MAT a, ade2-1; his3-11,15; leu2-3,112; ura3; trp1; can1-100; eRF3; pab1(1-490) ::TRP1Kl This study SKY1318 MAT a, ade2-1; his3-11,15; leu2-3,112; ura3; trp1; can1-100; eRF3::eRF3NM(253-685) 
This study SKY1319 MAT a, ade2-1; his3-11,15; leu2-3,112; ura3; trp1; can1-100; eRF3 ;PAB1 This study
SKY1320
MAT a, 15; 112; ura3; trp1; BSY1537 MAT a, ade2-1; his3-11; leu2-3,112; trp12; ura3-52; pab1(1-490) ::TRP1 Kl (Simon and Seraphin 2007) BSY1552 MAT a, 112; trp12; ::TRP1 Kl (Simon and Seraphin 2007) BSY1664 MAT a, 112; trp12; ::TRP1 Kl (Simon and Seraphin 2007) HFY870 MATa, ade2-1; his3-11,15; leu2-3,112; ura3-1; trp1-1; can1-100; upf1::HIS3; UPF2; UPF3 (He and Jacobson 1995) HFY1300 MATa, 15; 112; UPF1; nmd2::HIS3; UPF3 (He and Jacobson 1995)
Supplementary Table S2 -Oligonucleotides used in this study. Name  Sequence   SKO1  CTGCCCACGAATTCGAATGTCGGATTCAAACCAA  SKO2  TGTTTGCACTCGAGTTACTCGGCAATTTTAACAA  SKO9  CTGCCCACGGATCCGTATGTCGGATTCAAACCAAGGC  SKO21  ATCTTTACCCTCGAGTTAATCGTTAACAACTTCGTCATC  SKO53  CATTGTTGCTAGTGGGCAGATATAGATGTTAT  SKO56  ATCTATATCTGCCCACTAGCAACAATGTTTGGTGGTAAAGATCACGTTTCT  SKO73  ACGTAAGGATCCCTCAATTGGCTCAACAAATCCAAGCCA  SKO75  CCAAAGAGGATCCTGCCACCTCAATTTAGAAATGGTCCG  SKO77  TGATTACATCTGCAGTTAAGCTTGCTCAGTTTGTTGTTC  SKO86  TGACAGCGGCACTACAAGAC  SKO87  GCAGCGAAGGACCAAAGGAC SKO92  AAAGAGGATCGCCATTGAGG  SKO104  ATCTTTACCGAGCTCTTAATCGTTAACAACTTCGTCATC  SKO105  ACCAATAAAGGATCCATGGCTGATATTACTGATAAGACA  SKO108  TGATTACATGAGCTCTTAAGCTTGCTCAGTTTGTTGTTC  SKO112  CTGCCCACGGATCCGTATGTCTTTGAACGACTTTCAAAA  SKO126  GTCGTTCTCGAGTTAACCTTGAGACTGTGGTTG  SKO144  TATACCATAAACAAGGTAAACTTCACCTCTCAATATATCTAGCGTACGCTGCAGGTCGAC  SKO145 GGTATTATTGTGTTTGCATTTACTTATGTTTGCAAGAAATATCGATGAATTCGAGCTCG
Cloning oligonucleotides
Probes for Northern blotting
CCCATGCCATGATGTTAACCGGTTTAAT eRF3 promotor-eRF3-NM coding sequence-eRF3 terminator SKP239 pRS313 eRF3 promotor-eRF3 coding sequence-eRF3 terminator LMP241 pACTII eRF3-NM-AAA in fusion with GAL4 activation domain (AD) LMP272 pACTII eRF3-AAA in fusion with GAL4 activation domain (AD) SKP275 pACTII eRF3-N in fusion with GAL4 activation domain (AD) SKP278 pACTII eRF3-M in fusion with GAL4 activation domain (AD) SKP327 pRS313 eRF3 promotor-eRF3-AAA coding sequence-eRF3 terminator SKP364 pRS423-TEF PAB1 under the control of a promotor TEF for overexpression SKP418 pRS425 PGK1-pG under the control of tetO repressible promotor
Mutagenesis oligonucleotides
F92A (1) CAAGGCGGTTATCAGCAGCAAGCCAATCCACAAGG F92A (2) CCTTGTGGATTGGCTTGCTGCTGATAACCGCCTTG F104A (1) GGTGGCCGTGGAAATTACAAAAACGCCAACTACAATAAC F104A (2) GTTATTGTAGTTGGCGTTTTTGTAATTTCCACGGCCACC F117A (1) GCAAGGATATCAAGCTGGTGCCCAACCACAGTCTC F117A (2) GAGACTGTGGTTGGGCACCAGCTTGATATCCTTGC P138A (1) GCAGGCCGCTGCCAAACCAAAGAAGACTTTG P138A (2) CAAAGTCTTCTTTGGTTTGGCAGCGGCCTGC S148A-S150A (1) GACTTTGAAGCTTGTCGCCAGTGCCGGTATCAAGTTGG S148A-S150A (2) CCAACTTGATACCGGCACTGGCGACAAGCTTCAAAGTC K160A (1) GGCCAATGCTACCAAGGCGGTTGGCACAAAACCTG K160A (2) CAGGTTTTGTGCCAACCGCCTTGGTAGCATTGGCC K160E (1) GCTACCAAGGAGGTTGGCACAAAACCTGCCGAATC K160E (2) GATTCGGCAGGTTTTGTGCCAACCTCCTTGGTAGC K142A (1) GCCGCTCCCAAACCAAAGGCGACTTTGAAGCTTGTCTC K142A (2) GAGACAAGCTTCAAAGTCGCCTTTGGTTTGGGAGCGGC Supplementary
SUPPLEMENTARY MATERIALS AND METHODS
Plasmids construction
The plasmids pET22-PAB1His 6 , pGEX-GST-eRF3, and pET-eRF1His 6 used for expression and purification from E. coli were described previously (Heurgue-Hamard et al. 2005; Kervestin et al. 2012) . For construction of the plasmid pGEX-GST-eRF3-C, the oligonucleotide GST-XhoI-delC (GGCTCGAGTTAATCGTTAACAACTTCGTC) was used instead for XhoI-SUP35-3'. pGEX-GST-eRF3-AAA was obtained by direct mutagenesis on pGEX-GST-eRF3. Plasmid SKP364 used to overexpress Pab1 contains the PAB1 coding sequence amplified by PCR with oligonucleotides SKO105-SKO108 on genomic DNA and inserted at BamHI, EcoRI sites of pRS423-TEF (a gift from J. Banroques).
Inhibition of transcription by thiolutin
The drug thiolutin was used to inhibit transcription by RNA polymerase II as described in Sinturel et al. 2012 . The experimental conditions had to be carefully set up because thiolutin can have indirect effects (Pelechano and Pérez-Ortín 2008) . First we used an aliquot from another lab and determined that the optimal thiolutin concentration was 5 µg/ml for our strain background, and indirect mRNA stabilization started to appear at 10 µg/ml (data not shown).
We then used commercial thiolutin from Sigma (reference T3450) and determined that the optimal concentration was 10 µg/ml.
Protein purification and pull-down assay
Expression and purification of Pab1-His 6 , GST-eRF3 full-length, NM or AAA and eRF1-His 6
were performed as described (Heurgué-Hamard et al. 2006; Kervestin et al. 2012) . Pull-down experiments were performed as described (Kervestin et al. 2012 ) except that anti-eRF3
antibodies were used and quantification was performed on a Chemidoc XRS system from Biorad. In strains SKY1085 (eRF3), SKY1182 (eRF3NM), SKY1265 (pab1LC), SKY1263
SUPPLEMENTARY REFERENCES
(eRF3NM, pab1LC), transcription was inhibited by addition of thiolutin at time 0 and total RNA was extracted at the different time points indicated and analyzed by Northern blotting.
The blot was probed with 32 P-labelled oligonucleotides "TIF51a" and "SCR1" to detect, respectively, TIF51a mRNA and the noncoding SCR1 transcript as a control. After quantification, the signal at time point 0 was set at 100% of TIF51a mRNA and used as a reference to determine the percentage of mRNA remaining and TIF51a mRNA half-life. deposited on plate and their growth was scored after 2 days of growth at 30°C.
